Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage
Phase 2
Completed
- Conditions
- Intubation, Nasogastric
- Interventions
- Device: NG Shield
- Registration Number
- NCT00781248
- Lead Sponsor
- Nanovibronix
- Brief Summary
The purpose of the study i to demonstrate the safety and efficacy of a device that intends to reduce pain/discomfort related to nasogfastric tube usage by reducing the friction between the tube and internal orifice (nose and pharynx)using micro vibrations
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Subject is in good health and able to undergoes the NG tube insertion procedure, according to the PI decision
- Subject is able to understand and answer the pain and discomfort questionnaires
- Subject has been fasting for at least 12h prior to the insertion phase
- Subject underwent a physical examination by the PI
- Subject able, agrees and signs the Inform Consent Form (ICF)
Exclusion Criteria
- Subject has any history of dysphagia or esophageal disease
- Subject used anti pain medications during the last week prior to the study date
- Subject used Antibiotics during the last week prior to the study date
- Subject with Asthma
- Subject with chronic or acute nasal or throat disorder
- Subject who suffered from upper respiratory infection at least 7 days prior to the insertion procedure
- Any pain from other source prior to the initiation of the study procedure according to the PI judgment and decision
- Subject has any condition, which precludes compliance with study and/or device instruction for use
- Subject is currently participating in another clinical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 2 NG Shield Starting with inactive NG Shield 1 NG Shield starting with active NG Shield
- Primary Outcome Measures
Name Time Method Pain/discomfort levelusing flicker scale (1-10 scale)during indwelling phase every 30 minutes for 6 hours safety of device usage 6 hours
- Secondary Outcome Measures
Name Time Method pain/Dicomfort during insertion and removal of the nasogastric tube at t=0h and t=6h
Trial Locations
- Locations (1)
"Bikur Cholim" Hospital
🇮🇱Jerusalem, Israel